10don MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
CRISPR Therapeutics (CRSP) posts new data from an early stage trial for CTX310, an in vivo gene editing therapy for heart ...
In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like ...
Crispr Therapeutics reported end-2024 results in line with our expectations and Crispr’s diverse pipeline is continuing to make progress. We maintain our fair value estimate of $106 per share and view ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback